theranosfilm / independent analysis

02 / Technology and proof

Small sample.
Enormous promise.

A finger-prick sample, a testing machine and a laboratory service are not the same invention. Understanding the differences is the starting point.

Scientific explanation + preliminary documentary evidence

What would the system have to do?

At least four jobs: collect a usable sample, prepare it, measure the substances of interest and turn those measurements into reliable clinical results. A convincing demonstration of one job does not establish all four.

Blood tests measure different things: cells, proteins, small molecules and genetic material. They need different reactions, instruments or preparation. Shrinking the sample does not remove those requirements. Collection, transport and processing can introduce error before a measurement begins.

Why “platform” needs unpacking

A platform might integrate several testing methods, automate preparation, or provide a common instrument and software environment. It does not necessarily mean one universal sensor can perform every test. Ask which assays, on which sample types, with what preparation, throughput and error limits.

Theranos’s 2016 technology announcement is a company account of its proposed integrated system, not independent validation. Early concepts, Edison and miniLab must be examined as different stages, not treated as one unchanged device.

What counts as showing that it works?

For each assay, an investigator should seek evidence of accuracy against an appropriate comparator, repeatability, sensitivity where relevant, measurement range, interference, failed runs and performance across realistic samples. Clinical usefulness and permission to offer a test are further questions. One successful result cannot validate an entire test menu.

The question to ask of every demonstration

Did this result come from the claimed device, using the claimed sample and workflow, without undisclosed outside processing—and was performance reliable beyond that selected example?

What independent evidence adds

A 2016 JCI study compared 22 tests across Theranos, Quest and LabCorp in 60 healthy adults. It reported differences between services. Its scope was delivered testing, not a complete inspection of every proprietary instrument or an assessment of every patient population. It should not be used to infer which internal machine produced every result.

What was the intellectual property?

US8283155B2 is a starting point for point-of-care fluidic-system claims. A proper audit must distinguish the granted claims, ownership, relevant dates, validity questions and the product actually built. Patent protection does not certify clinical accuracy or commercial readiness. We have not completed that audit.

“They were using the wrong technology”

The exact exchange still needs verification against the film. “Wrong” could refer to sample preparation, detection method, engineering architecture, development sequence or economics. Those are competing hypotheses—not established explanations. We need the speaker’s identity, full question and answer, dates and a technical comparison before choosing among them.

A later approach is not automatically proof that an earlier approach was impossible. Nor does a patent application for a later approach establish that it works.

A later optical approach is a separate claim to test

Earlier research located Haemanthus application US20250277744A1, naming Joseph G. LaChapelle and Roger S. Cannon and describing a Raman approach. This is a research pointer, not a completed patent-claims audit or verification of the film exchange.

Raman spectroscopy uses scattered light to obtain information about molecular vibrations. Turning a mixed biological sample’s optical signal into reliable clinical measurements still requires calibration, interference testing and independent validation. Changing the measurement principle does not remove the obligation to demonstrate useful performance.

What remains outside this explanation

We still need an assay-by-assay account of what was claimed, actually run, independently validated and disclosed. The site will not claim that all blood testing from small samples is impossible, or that scientific possibility excuses a misleading claim of present performance.

Next: What investors were told · Source register